Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04768491
Other study ID # NCC2439
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date October 31, 2024

Study information

Verified date February 2021
Source Peking Union Medical College
Contact Puyuan Xing, PhD
Phone +86-10-87788495
Email xingpuyuan@cicams.ac.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.


Description:

This is a multi-center observational study with both retrospective and prospective data collections to describe the effectiveness and safety of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance in a clinical practice setting. The study will include patients who were or will be diagnosed as advanced NSCLC with EGFR mutation positive and received dacomitinib as first-line treatment followed by second-line 3rd generation EGFR-TKI treatment in multiple tertiary care hospitals after Sep 1st, 2019. Patients' clinical information prior to the study initiation in each hospital will be collected retrospectively through chart review. After the study initiation, new patient enrollment will last till Dec 2022. Patients' clinical care after the study initiation will be followed up prospectively until the end of study. The interval of response evaluation is recommended to be every 2 to 3 months in the treatment period and the interval of follow-up is recommended to be every 2 to 3 months in the post-treatment period till the end of study in the prospective data collection period.


Recruitment information / eligibility

Status Recruiting
Enrollment 82
Est. completion date October 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A confirmed diagnosis of locally advanced or metastatic NSCLC. - The tumor harbored common EGFR mutations (Del19, L858R) at start of first-line treatment - Age = 18 years - Had never received any EGFR TKI therapy. - Patients that treated with dacomitinib (Vizimpro®) as first-line treatment - Confirmation of the T790M variant after first line dacomitinib treatment and receive any 3rd generation EGFR-TKI as second-line treatment. - Asymptomatic CNS metastases allowed - At least one lesion that can be accurately measured at baseline according to the RECIST 1.1, and which is suitable for accurate repeated measurements. - Start second-line treatment with third generation EGFR TKI no later than 01 JAN2023(>10 month before data cutoff date) - All eligible patients are required to sign an informed consent before initiating the study Exclusion Criteria: - Patients who received drug(s) other than 3rd generation EGFR-TKI as the second-line treatment and/or patients who received drug(s) other than Dacomitinib (Vizimpro®) as the first-line treatment - Received or currently receiving dacomitinib from any interventional clinical trial

Study Design


Intervention

Drug:
Dacomitinib
effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.

Locations

Country Name City State
China National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary time to treatment failure To describe the time to treatment failure (TTF) of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC and T790M-aquired resistance in China. up to 4 years
Secondary progression-free survival To describe the progression-free survival (PFS) of dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance in China. up to 4 years
Secondary duration of treatment To describe the duration of treatment (DOT) of dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance respectively in China. up to 4 years
Secondary overall survival To describe the overall survival (OS) of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC and T790M-aquired resistance in China. up to 5 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05543330 - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Phase 1/Phase 2
Recruiting NCT04106180 - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Phase 2
Recruiting NCT05215548 - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC Phase 2
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04467801 - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Phase 2
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Not yet recruiting NCT04492969 - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting NCT04116918 - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated NCT03411473 - Study of AGEN1884 With Pembrolizumab in 1L NSCLC Phase 2
Recruiting NCT03564197 - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC N/A
Not yet recruiting NCT06219317 - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Phase 2
Not yet recruiting NCT04604470 - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting NCT04136535 - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC Phase 2
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Completed NCT06339554 - Alectinib-induced Endocrine Toxicity
Active, not recruiting NCT04549428 - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC Phase 2
Recruiting NCT03647956 - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors Phase 2
Recruiting NCT04180501 - SRS Sequential Sindilimab in Brain Metastasis of NSLSC Phase 2